Format

Send to

Choose Destination
Clin Immunol. 2007 Sep;124(3):235-7. Epub 2007 Jul 26.

Syk kinase as a treatment target for therapy in autoimmune diseases.

Author information

1
Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Institutes of Medicine, HIM-238, 4 Blackfan Circle, Boston, MA 02115, USA. vkyttari@bidmc.harvard.edu

Abstract

Spleen tyrosine kinase (Syk) associates with a variety of immunoreceptors in myeloid and lymphoid cells. Syk initiates intracellular signaling once the receptor is engaged by its ligand. Blocking Syk may prove beneficial in interrupting the propagation of the abnormal immune response in both autoimmune and allergic diseases.

PMID:
17662659
PMCID:
PMC1986716
DOI:
10.1016/j.clim.2007.06.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center